Basic Aspects of Catechol-O-Methyltransferase and the Clinical Applications of its Inhibitors, Volume 95

1st Edition

Series Volume Editors: Erkki Nissinen
Hardcover ISBN: 9780123813268
eBook ISBN: 9780123813275
Imprint: Academic Press
Published Date: 2nd December 2010
Page Count: 336
198.00 + applicable tax
155.00 + applicable tax
124.00 + applicable tax
204.00 + applicable tax
Unavailable
Compatible Not compatible
VitalSource PC, Mac, iPhone & iPad Amazon Kindle eReader
ePub & PDF Apple & PC desktop. Mobile devices (Apple & Android) Amazon Kindle eReader
Mobi Amazon Kindle eReader Anything else

Institutional Access


Table of Contents

  1. Introductory remarks: Catechol-O-methyltransferase inhibition: an innovative approach to enhance L-dopa therapy in Parkinson’s disease with dual enzyme inhibition
  2. Erkki Nissinen

  3. The catechol-O-methyltransferase gene, its regulation and polymorphisms
  4. Elizabeth M. Tunbridge

  5. Distribution and functions of catechol-O-methyltransferase proteins: do recent findings change the picture?
  6. Timo T. Myöhänen & Pekka T. Männistö

  7. Catechol-O-methyltransferase enzyme: Cofactor S-adenosyl-L-methionine and related mechanisms
  8. Thomas Müller

  9. Biochemistry and pharmacology of catechol-O-methyltrasferase inhibitors
  10. Erkki Nissinen and Pekka T. Männistö

  11. The Chemistry of Catechol-O-methyltransferase Inhibitors
  12. David A. Learmonth, László E. Kiss and Patrício Soares-da-Silva

  13. Toxicology and safety of COMT inhibitors
  14. Kristiina Haasio

  15. Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of the L-dopa treatment
  16. Concepció Marin, J.A. Obeso

  17. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson’s disease
  18. Seppo Kaakkola

  19. Catechol-O-methyltransferase and pain

Oleg Kambur & Pekka T. Männistö


Description

Volume 95 of International Review of Neurobiology focuses on Catechol-O-methyltransferase inhibition, and its clinical application in relation to Parkinson’s disease. Chapters cover COMT gene and proteins, L-dopa treatment in Parkinson’s disease, the latest research on COMT inhibitors and their clinical applications, as well as future prospects for their use.

Key Features

Up-to-date summary of biochemistry and pharmacology of COMT and its inhibitors
Preclinical models in COMT inhibitor devlopment
Transgenic COMT mice – latest information summarized
Chemistry of COMT inhibitors and their design with molecular modelling
COMT gene and its regulation and relation to dopamine related diseases
Role of cofactor SAM regulation in relation to homocysteine
Nonclinical and clinical safety of COMT inhibitors summarized
Future prospects of COMT inhibitors in Parkinson’s disease

Readership

Neuroscientists, neurologists, psychologists, gerontologists


Details

No. of pages:
336
Language:
English
Copyright:
© Academic Press 2010
Published:
Imprint:
Academic Press
eBook ISBN:
9780123813275
Hardcover ISBN:
9780123813268

About the Series Volume Editors

Erkki Nissinen Series Volume Editor

Affiliations and Expertise

Orion Corporation, Espoo, Finland